Relationships between quantitative electroencephalographic alterations and the severity of hepatitis C based on liver biopsy in interferon-alpha treated patients.

OBJECTIVE We have observed alterations of quantitative (q)-EEG findings occurring in interferon (IFN)-alpha treated chronic hepatitis C (CH-C) patients, and found patient's age to be one factor influencing such EEG alterations. In the present study we evaluated the correlation between q-EEG alterations during IFN-alpha treatment and the severity of hepatitis based on liver biopsies. METHODS A total of 102 CH-C patients underwent blind, prospective and serial q-EEG examinations. The IFN-alpha was administered under the same therapeutic regimen to all patients. Serial EEGs were obtained before, at 2 and 4 weeks, and at 2-3 days after the conclusion of treatment. The absolute powers of each frequency band in different periods were determined by q-EEG. Staging (of fibrosis) and grading (of inflammatory cell infiltration) were scaled according to Desmet's classification. We evaluated the relationship between q-EEG and scales of staging or grading. RESULTS Age distributions did not differ significantly among stages or grades. As the stage or grade increased, the alterations of EEG during IFN-alpha treatment became more pronounced, and significant (repeated-measures analysis of variances; both, p<0.0001). CONCLUSION Alterations of the EEG occurring during IFN-alpha treatment became pronounced with more severe pathological findings for CH-C. Alterations in the EEGs during IFN-alpha treatment should be carefully monitored in CH-C patients with severe pathological findings.

[1]  M. Matsuura,et al.  Correlation Between Quantitative-EEG Alterations and Age in Patients With Interferon-α–Treated Hepatitis C , 2005, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[2]  M. Matsuura,et al.  Alterations of Quantitative EEG and Mini-Mental State Examination in Interferon-α-Treated Hepatitis C , 2002, European Neurology.

[3]  T. Takasu,et al.  Blinded, prospective, and serial evaluation by quantitative‐EEG in interferon‐alpha‐treated hepatitis‐C , 1999, Acta neurologica Scandinavica.

[4]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[5]  R. Scheibel,et al.  Persistent neurotoxicity of systemically administered interferon‐alpha , 1991, Neurology.

[6]  T. Lister,et al.  Central nervous system toxicity of interferon. , 1983, British Journal of Cancer.

[7]  K. Sikora,et al.  Neurological effects of recombinant human interferon. , 1983, British medical journal.

[8]  E. M. Smith,et al.  Human leukocyte interferon: structural and biological relatedness to adrenocorticotropic hormone and endorphins. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Blalock,et al.  Common pathways of interferon and hormonal action , 1980, Nature.

[10]  M. Rizzetto,et al.  THERAPY OF CHRONIC VIRAL HEPATITIS , 1999 .

[11]  F. Arenzana‐Seisdedos,et al.  Interferons as macrophage‐activating factors. II. Enhanced secretion of interleukin 1 by lipopolysaccharide‐stimulated human monocytes , 1983, European journal of immunology.